44. (Withdrawn) The method of making a current released drug delivery device of claim 42 wherein the crosslinking agents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido-2 nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4'azido-2'nitro-phenylamino]hexanoate and 4 [p-Azidosalicylamido] butylamine.

45. (Withdrawn) The method of making a current released drug delivery device of claim 43 wherein the one or more crosslinking reagents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido 2-nitrobenzoyioxysuccinimide, N-Succinimidyl 6-[4'azido-2'nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.

46. (Withdrawn) The method of making a current released drug delivery device of claim 18 wherein the one or more conductive materials are selected from the group consisting of gold, silver, aluminum, platinum, tungsten, stainless steel, nitinol, copper, niobium, titanium, and ceramics.

47. (Withdrawn) The method of making a current released drug delivery device of claim 19 wherein the one or more conductive materials are selected from the group consisting of gold, silver, aluminum, platinum, tungsten, stainless steel, nitinol, copper, niobium, titanium, and ceramics.

48. (Withdrawn) The method of making a current released drug delivery device of claim 18 wherein the one or more conductive materials comprises an alloy including one or more

substances selected from the group consisting of gold, silver, tungsten, niobium, cobalt, titanium, zirconium, vanadium, molybdenum, nickel, iron, zinc, and copper.

49. (Withdrawn) The method of making a current released drug delivery device of claim 19 wherein the one or more conductive materials comprises an alloy including one or more substances selected from the group consisting of gold, silver, tungsten, niobium, cobalt, titanium, zirconium, vanadium, molybdenum, nickel, iron, zinc, and copper.

50. (Currently Amended) An electromatrix device comprising one or more biocompatible protein materials, one or more conductive materials, zero or more pharmacologically active agents and one or more biocompatible solvents, wherein the protein materials, conductive materials, pharmacologically active agents and biocompatible solvents are formed into a non-brittle cohesive body prior to compression and the cohesive body is compressed to remove bulk biocompatible solvent and generate additional interactive forces to form the electromatrix device.

51. (Original) The electromatrix device of claim 50 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.

52. (Original) The electromatrix device of claim 51 wherein the biocompatible proteins are natural proteins selected from the group consisting of elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.

53. (Withdrawn) The electromatrix device of claim 51 wherein the biocompatible proteins are genetically engineered proteins made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.

54. (Original) The electromatrix device of claim 50 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.

55. (Original) The electromatrix device of claim 54 wherein the biocompatible solvent is water.

56. (Withdrawn) The electromatrix device of claim 50 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombogenic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.

57. (Withdrawn) The electromatrix device of claim 50, wherein the pharmacologically active agents comprises a second, migration vulnerable drug delivery device.

58. (Withdrawn) The electromatrix device of claim 57, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the electromatrix device.

59. (Withdrawn) The electromatrix device of claim 57, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the electromatrix device.

60. (Withdrawn) The electromatrix device of claim 50, wherein the pharmacologically active agent is substantially homogeneously distributed within the electromatrix device.

61. (Original) The electromatrix device of claim 50 further comprising one or more biocompatible polymeric materials.

62. (Currently Amended) The electromatrix device of claim 61 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate polymers, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane polymers, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, poly(ethylene

oxide), poly ortho esters, polycyanoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based polymers, isopropyl styrene polymers, vinyl pyrrolidone polymers, cellulose acetate dibutyrate, ~~and~~ silicone rubber, and combinations of these.

63. (Original) The electromatrix device of claim 50 wherein the current released drug delivery device is crosslinked with one or more crosslinking agents.

64. (Original) The electromatrix device of claim 63 wherein the one or more crosslinking reagents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido 2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4'azido-2'nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.

65. (Previously Presented) The electromatrix device of claim 50 wherein the one or more conductive materials are selected from the group consisting of gold, silver, aluminum, platinum, tungsten, stainless steel, nitinol, copper, niobium, titanium, and ceramics.

66. (Original) The electromatrix device of claim 50 wherein the one or more conductive materials comprises an alloy including one or more substances selected from the group consisting of gold, silver, tungsten, niobium, cobalt, titanium, zirconium, vanadium, molybdenum, nickel, iron, zinc, and copper.